Table 1.
Characteristics of the patients.
| BMC (n = 11) | Control (n = 8) | p | |
|---|---|---|---|
| Male gender, n (%) | 11 (100%) | 8 (100%) | 1.00 |
| Age, years | 56 ± 12 | 55 ± 9 | 0.89 |
| Body mass index, kg/m2 | 26 (26–28) | 26 (24–27) | 0.49 |
| Hypertension, n (%) | 5/11 (45%) | 2/8 (25%) | 0.63 |
| Hypercholesterolemia, n (%) | 3/11 (27%) | 3/8 (38%) | 1.00 |
| Diabetes mellitus, n (%) | 1/11 (9%) | 0/8 (0%) | 1.00 |
| Current smoking, n (%) | 3/11 (27%) | 3/8 (38%) | 0.61 |
| SEVERITY OF CAD n (%) | |||
| Previous AMI | 2 (18%) | 1 (13%) | 1.00 |
| Previous angina pectoris | 1/11 (9%) | 2/8 (25%) | 0.55 |
| 1-Vessel disease | 5/11 (46%) | 5/8 (63%) | 0.65 |
| 2-Vessel disease | 4/11 (36%) | 3/8 (38%) | 1.00 |
| 3-Vessel disease | 2/11 (18%) | 0/8 (0%) | 0.49 |
| INDEX EVENT AND PERCUTANEOUS CORONARY INTERVENTION | |||
| Symptoms to thrombolysis time, hours | 2.0 (1.2) | 2.9 (2.0) | 0.27 |
| Highest troponin value, μg/L | 2.3 (0.7–3.8) | 1.0 (1.0–2.0) | 0.37 |
| From reperfusion to study therapy, days | 3.2 (1.0) | 3.1 (1.2) | 0.84 |
| Infarct-related artery, n (%) | |||
| LAD | 3/11 (27%) | 4/8 (50%) | 0.38 |
| LCX | 2/11 (18%) | 3/8 (38%) | 0.60 |
| RCA | 6/11 (55%) | 1/8 (13%) | 0.15 |
| Target lesion stenosis, % | 80 (60–94) | 70 (59–99) | 0.34 |
| TIMI FLOW BEFORE PCI | |||
| 0 | 2/11 (18%) | 0/8 (0%) | 0.49 |
| 1 | 2/11 (18%) | 2/8 (25%) | 1.00 |
| 2 | 0/11 (0%) | 2/8 (25%) | 0.16 |
| 3 | 7/11 (64%) | 4/8 (50%) | 0.66 |
| TIMI FLOW AFTER PCI | |||
| 3 | 11/11 (100%) | 8/8 (100%) | 1.00 |
| Drug-eluting stents | 11/11 (100%) | 8/8 (100%) | 1.00 |
| GPIIb/IIIa inhibitor during acute PCI | 2/11 (18%) | 1/8 (13%) | 1.00 |
| LEFT VENTRICULAR PARAMETERS BY ANGIOGRAPHY BEFORE STUDY THERAPY | |||
| EF, % | 66.9 ± 5.2 | 55.1 ± 18.3 | 0.15 |
| EDV, mL | 161 ± 48 | 154 ± 32 | 0.74 |
| ESV, mL | 57.0 (38.5–61.7) | 53.6 (46.6–86.4) | 0.44 |
| STUDY THERAPY | |||
| Amount of injected CD34+ * 106 | 2.9 ± 2.0 | placebo | NA |
| Viability of cells, % | >95% | – | NA |
| CARDIAC MEDICATION AT DISCHARGE, n (%) | |||
| Aspirin | 11/11(100%) | 8/8 (100%) | 1.00 |
| Clopidogrel | 11/11(100%) | 8/8 (100%) | 1.00 |
| β-Blocker | 10/11 (91%) | 8/8 (100%) | 1.00 |
| ACE inhibitor or ATII blocker | 9/11 (82%) | 7/8 (88%) | 1.00 |
| Statin | 11/11(100%) | 8/8 (100%) | 1.00 |
| Diuretics | 1/11 (9%) | 6/8 (75%) | 0.006 |
| Nitrate | 5/11 (46%) | 2/8 (25%) | 0.63 |
| Calcium antagonists | 0/11 (0%) | 0/8 (0%) | 1.00 |
| Digitalis | 1/11 (9%) | 4/8 (50%) | 0.11 |
| CARDIAC MEDICATION AT 6 MONTH FOLLOW-UP, n (%) | |||
| Aspirin | 11/11 (100%) | 8/8 (100%) | 1.00 |
| Clopidogrel | 10/11 (91%) | 8/8 (100%) | 1.00 |
| β-Blocker | 10/11 (91%) | 8/8 (100%) | 1.00 |
| ACE inhibitor or ATII blocker | 9/11(82%) | 7/8 (88%) | 1.00 |
| Statin | 11/11(100%) | 8/8 (100%) | 1.00 |
| Diuretics | 1/11(9%) | 2/8 (25%) | 0.55 |
| Nitrate | 1/11(9%) | 2/8 (25%) | 0.55 |
| Calcium antagonists | 0/11 (0%) | 0/8 (0%) | 1.00 |
| Digitalis | 0/11 (0%) | 0/8 (0%) | 1.00 |
Continuous variables with normal distribution are expressed as mean ± SD and with a non-parametric distribution as median (lower-upper quartile), categorical variables as frequency (percent). Independent sample T-test combined to Levene’s test were applied for continuous variables with normal distribution, and Mann–Whitney U test for variables with non-parametric distribution. Chi-square/Fisher’s exact test was used for categorical variables as appropriate. All tests were performed two-tailed. CAD, coronary artery disease; AMI, acute myocardial infarction; LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; RCA, right coronary artery; PCI, percutaneous coronary intervention; GP, glycoprotein; EF, ejection fraction; EDV, end-diastolic volume; ESV, end-systolic volume; ACE, angiotensin-converting enzyme; AT, angiotensin receptor.